News

Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate
Gain insights into Amneal Pharmaceuticals' Q2 2025 success, with strong growth, upgraded guidance, and promising launches like CREXONT and Brekiya.
Amneal Pharma’s Optimistic Q2 Earnings Call Highlights
Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.